Brevan Howard Capital Management LP Atea Pharmaceuticals, Inc. Transaction History
Brevan Howard Capital Management LP
- $12.7 Billion
- Q1 2024
A detailed history of Brevan Howard Capital Management LP transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 20,809 shares of AVIR stock, worth $68,253. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,809
Previous 25,717
19.08%
Holding current value
$68,253
Previous $78,000
7.69%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AVIR
# of Institutions
119Shares Held
49.6MCall Options Held
108KPut Options Held
327K-
Black Rock Inc. New York, NY9.24MShares$30.3 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.15MShares$20.2 Million0.71% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.54MShares$18.2 Million14.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$15.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.08MShares$13.4 Million2.01% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $273M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...